secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001213900-23-082184
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Q3 net loss $8.6M; XPro Phase II AD trial advances, INKmune on track
-------------------------------------------------------------------------------

- Net loss $8.6M vs $7.7M YoY; R&D $6.0M; cash $41.8M as of Sept 30.
- MHRA authorized XPro Phase II trial in early AD; recruitment increasing; top-line results expected end-2024.
- FDA clinical hold on XPro for CNS expected to be lifted by end-2023.
- INKmune Phase I/II in mCRPC to enroll first patient by year-end 2023; LAUREL trial in MDS/AML third site active.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/0001213900-23-082184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/ea187584-8k_inmunebio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-082184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer